SCHEMBL1049963

SCHEMBL1049963

O=C1NC(=O)c2c([N+](=O)[O-])ccc3cccc1c23

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.50
S100A4 P26447 2/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
POLB P06746 3/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
PTPRC P08575 1/20 0.44
MAPT P10636 2/20 0.43
RXFP1 Q9HBX9 2/20 0.43
RECQL P46063 1/20 0.43
MCL1 Q07820 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
GSK3B P49841 2/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612017 0.83 PARP1 (0.53) PARP1SMN1; SMN2S100A4KMT2AMEN1
SCHEMBL28914061 0.81 PARP1 (0.47) PARP1SMN1; SMN2S100A4KMT2AMEN1
SCHEMBL284027 0.80 SMN1; SMN2 (0.61) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL30050991 0.80 SMN1; SMN2 (0.61) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL14257644 0.80 S100A4 (0.61) SMN1; SMN2S100A4KMT2AMEN1POLB
Methane SCHEMBL28163541 0.79 SMN1; SMN2 (0.60) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL28012557 0.79 SMN1; SMN2 (0.60) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL32674558 0.78 S100A4 (0.53) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL31677721 0.78 S100A4 (0.53) SMN1; SMN2S100A4KMT2AMEN1POLB
SCHEMBL4377088 0.78 S100A4 (0.53) SMN1; SMN2S100A4KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9655550-B2 Latent fingerprint detection method, heating evaporation device for detecting latent fingerprint, latent fingerprint detection apparatus, and composition for detecting latent fingerprint EARTH CHEMICAL CO., LTD. (JP) 2017-05-23 US claimed
US-20150245790-A1 LATENT FINGERPRINT DETECTION METHOD, HEATING EVAPORATION DEVICE FOR DETECTING LATENT FINGERPRINT, LATENT FINGERPRINT DETECTION APPARATUS, AND COMPOSITION FOR DETECTING LATENT FINGERPRINT TOAGOSEI, CO., LTD. (JP) 2015-09-03 US claimed
EP-1539150-A4 NAPHTHALIMIDE SYNTHESIS INCLUDING AMONAFIDE SYNTHESIS AND PHARMACEUTICAL PREPARATIONS THEREOF CHEMGENEX PHARMACEUTICALS INC (US) 2006-10-11 EP claimed
JP-2005533088-A 2005-11-04 JP claimed
EP-1539150-A1 NAPHTHALIMIDE SYNTHESIS INCLUDING AMONAFIDE SYNTHESIS AND PHARMACEUTICAL PREPARATIONS THEREOF Chemgenex Pharmaceuticals Limited (US) 2005-06-15 EP claimed
US-20040082788-A1 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof CHEMGENEX THERAPEUTICS, INC. 2004-04-29 US claimed
WO-2004004716-A1 NAPHTHALIMIDE SYNTHESIS INCLUDING AMONAFIDE SYNTHESIS AND PHARMACEUTICAL PREPARATIONS THEREOF CHEMGENEX PHARMACEUTICALS LIMITED (US) 2004-01-15 WO claimed
CN-113666869-B Naphthoimide dye containing amino group in supercritical CO 2 In (a) synthesis and dyeing method 大连工业大学 2023-11-14 CN disclosed
CN-107847188-B Composition for latent fingerprint detection 东亚合成株式会社 2022-03-25 CN disclosed
CN-113666869-A Naphthalimide dyes containing amino in supercritical CO2The synthesis and dyeing method of 大连工业大学 2021-11-19 CN disclosed
EP-3329846-B1 COMPOSITION FOR DETECTING LATENT FINGERPRINT TOAGOSEI CO LTD (JP) 2021-07-14 EP disclosed
US-20180368740-A1 COMPOSITION FOR DETECTING LATENT FINGERPRINT TOAGOSEI CO., LTD (JP) 2018-12-27 US disclosed
EP-3329846-A1 COMPOSITION FOR DETECTING LATENT FINGERPRINT Toagosei Co., Ltd. (JP) 2018-06-06 EP disclosed
EP-0283604-A2 Process for fabricating a belt XEROX CORPORATION (US) 1988-09-28 EP disclosed
EP-0149914-B1 OVERCOATED ELECTROPHOTOGRAPHIC IMAGING MEMBER XEROX CORPORATION (US) 1988-08-10 EP disclosed
US-4747992-A SEAMLESS XEROX CORPORATION 1988-05-31 US disclosed
EP-0171262-A2 Electrophotographic imaging member XEROX CORPORATION (US) 1986-02-12 EP disclosed
US-4557993-A Process for preparing an electrophotographic imaging member with NiO interlayer XEROX CORPORATION (US) 1985-12-10 US disclosed
EP-0149914-A1 Overcoated electrophotographic imaging member XEROX CORPORATION (US) 1985-07-31 EP disclosed
US-4515882-A CHARGE TRANSFER COMPOUNDS AND CHARGE INJECTION ENABLING PARTICLES XEROX CORPORATION (US) 1985-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082788-A1 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof NME4, MFN2, NDUFAB1 PARP1 910/4885SMN1; SMN2 1313/4885S100A4 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.